RAPT News and Press, RAPT Therapeutics Inc. From 01/20/26

2026-01-20 15:15:45 ET The last time I spoke about RAPT Therapeutics, Inc. ( RAPT ), it was in a Seeking Alpha article entitled " RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus ." With respect to this article, I primarily noted the development of its CCR4 antag...

NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion , a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a definitive agreement to acquire Forbion Growth Fund III portfolio company RAPT Therapeutics, Inc. ...

Shareholders should contact the firm as there may be limited time to enforce your rights. Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of RAPT Therapeutics, Inc. (NASDAQ: RAPT) to GSK plc for $58.00 per share is fair to RAPT shareholders. Halp...

2026-01-20 05:01:09 ET More on related stocks: ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Nvidia: Risks Continue To Loom - A Unique Value Trap For N...

2026-01-20 02:56:40 ET More on GSK, RAPT Therapeutics RAPT Therapeutics, Inc. (RAPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript GSK Still Has Room To Run Desp...

2026-01-14 20:45:58 ET RAPT Therapeutics, Inc. (RAPT) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 5:15 PM EST... Read the full article on Seeking Alpha For further details see: RAPT Therapeutics, Inc. (RAPT) Presents at 44th Annual J.P. Morgan Healthcare C...

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological disease...

2025-11-15 07:32:36 ET Topline Summary Read the full article on Seeking Alpha For further details see: RAPT Therapeutics: Strong Promise In Immunology, Looking Like An Opportunity At These Prices

2025-11-06 12:27:18 ET More on RAPT Therapeutics RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria - Slideshow RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous ...

- Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had comparable efficacy and safety to omalizumab at Q4W dosing - Completed $25...